The Different Facets of Dyslipidemia and Hypertension in Atherosclerosis

被引:0
作者
Jessica Hurtubise
Krystie McLellan
Kevin Durr
Oluwadara Onasanya
Daniel Nwabuko
Joseph Fomusi Ndisang
机构
[1] University of Saskatchewan College of Medicine,Department of Physiology
来源
Current Atherosclerosis Reports | 2016年 / 18卷
关键词
Endothelial dysfunction; Hypertension; Dyslipidemia; Low-density lipoprotein; High-density lipoprotein; Oxidative stress; Inflammation;
D O I
暂无
中图分类号
学科分类号
摘要
Atherosclerosis is the narrowing of arteries due to the accumulation of macrophages overloaded with lipids resulting in foam cell formation, and these events occur preferentially at the branching points of arteries which are particularly susceptible to hyperlipidemic stress-induced inflammation and oxidative stress. The different stages of atherogenesis rely on oxidative stress, endothelial dysfunction, and inflammation, and hypertension or dyslipidemia can independently trigger these stages. Dyslipidemia and hypertension are pathological conditions that damage the endothelium, triggering cell proliferation, vascular remodeling, apoptosis, and increased cellular permeability with increased adhesion molecules that bind monocytes and T lymphocytes to create a vicious cocktail of pathophysiological factors. Correspondingly, the factors are redirected by chemo-attractants and pro-inflammatory cytokines into the intima of the vasculature, where monocytes differentiate into macrophages taking up oxidized LDL uncontrollably to form foam cells and atherosclerotic lesions. Moreover, endothelial damage also causes loss of vasomotor activity, disproportionate vascular contractility, and elevation of blood pressure in dyslipidemic patients, while in hypertensive patients, further elevation of blood pressure occurs, creating a self-perpetuating vicious cycle that aggravates the development and progression of atherosclerotic lesions. This review offers an in-depth analysis of atherosclerosis and the related interplay between dyslipidemia/hypertension and critically appraises the current diagnosis, etiology, and therapeutic options.
引用
收藏
相关论文
共 271 条
[1]  
Selvin E(2005)Glycaemia (haemoglobin A1c) and incident ischaemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study The Lancet Neurology 4 821-826
[2]  
Coresh J(2002)Inflammation in atherosclerosis Nature 420 868-874
[3]  
Shahar E(1983)Carotid bifurcation atherosclerosis. Quantitative correlation of plaque localization with flow velocity profiles and wall shear stress Circ Res 53 502-514
[4]  
Zhang L(2015)An experimental study on amelioration of dyslipidemia-induced atherosclesis by Clematichinenoside through regulating Peroxisome proliferator-activated receptor-alpha mediated apolipoprotein A-I, A-II and C-III Eur J Pharmacol 761 362-374
[5]  
Steffes M(2014)Association of longitudinal changes in left ventricular structure and function with myocardial fibrosis: the Multi-Ethnic Study of Atherosclerosis study Hypertension 64 508-515
[6]  
Sharrett AR(2015)Macrophages and immune cells in atherosclerosis: recent advances and novel concepts Basic Res Cardiol 110 34-55
[7]  
Libby P(2014)Impaired systolic blood dipping and nocturnal hypertension: an independent predictor of carotid intima-media thickness in type 1 diabetic patients J Diabetes Complicat 28 51-94
[8]  
Zarins CK(1997)Associations between carotid atherosclerosis and high factor VIII activity, dyslipidemia, and hypertension Stroke 28 88-319
[9]  
Giddens DP(2015)HDL cholesterol and stroke risk: the multi-ethnic study of atherosclerosis Atherosclerosis 243 314-345
[10]  
Bharadvaj BK(2013)Rational approaches to the treatment of hypertension: diet Kidney Int Suppl 3 343-208